<ENAMEX TYPE="ORGANIZATION">National Patent Development Corp.</ENAMEX> said it plans to purchase as many as 200,000 common shares of its 81%-controlled <ENAMEX TYPE="ORGANIZATION">Interferon Sciences Inc.</ENAMEX> unit in periodic, open-market purchases.
The 200,000 shares are about 23% of <ENAMEX TYPE="ORGANIZATION">Interferon</ENAMEX>'s common shares outstanding, excluding <ENAMEX TYPE="ORGANIZATION">National Patent</ENAMEX>'s stake.
Noting the recent <ENAMEX TYPE="ORGANIZATION">Food and Drug Administration</ENAMEX> approval of <ENAMEX TYPE="ORGANIZATION">Interferon</ENAMEX>'s genital warts treatment, <ENAMEX TYPE="ORGANIZATION">National Patent</ENAMEX> said it believes <ENAMEX TYPE="ORGANIZATION">Interferon</ENAMEX>'s stock is undervalued.
